Pharmaceutical News

RSS

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

pHase Pharmaceuticals launches new drug development company

pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

CSL Biotherapies comments on influenza vaccine paediatric adverse events

CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia.

23 Apr 2010

FDA rejects experimental painkiller Acurox

In a new development King Pharmaceuticals Inc. and Acura Pharmaceuticals Inc. have failed to win the approval of a US panel for marketing an experimental painkiller called Acurox.

23 Apr 2010

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan®, in 60 mg per 20 mL and 90 mg per 30 mL vials. IMS data indicate that the 2009 U.S. innovator market for these adenosine presentations approximated $124 million. The Company plans to launch the product upon expiry of applicable innovator patents.

23 Apr 2010

Colorcon acquires NP Pharm

Colorcon, Inc. today announced the acquisition of the full-service pharmaceutical excipient company, NP Pharm, a Division of Ethypharm. This acquisition expands Colorcon's global excipient product offerings in the pharmaceutical and nutritional markets.

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

Biostar Pharmaceuticals lists on NASDAQ Global Market

Biostar Pharmaceuticals, Inc., a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced that the Company was approved by NASDAQ to list its common stock on the NASDAQ Global Market. The Company's listing application was reviewed and approved by NASDAQ's Listing Qualifications Department for compliance with all of NASDAQ's standards.

23 Apr 2010

CRT teams up with The University of Auckland to discover novel treatments for cancer

Cancer Research Technology - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

The seasonal flu vaccine has caused serious side effects in dozens of children in Western Australia (WA) and following this the Health Department has suspended further free flu vaccinations for under-fives. There has been as rise in admissions to Princess Margaret Hospital. The side effects to the flu vaccine include fever, vomiting and often seizures related to high fever, also known as febrile convulsions. One of the children is seriously ill at present.

22 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

FDA announces draft guidance expanding transparency, disclosure in conflict of interest waivers

The U.S. Food and Drug Administration today announced draft guidance that would expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual's participation at an FDA advisory committee meeting.

22 Apr 2010

CancerDrugsDirect.com provides customers access to affordable cancer medications

When someone is diagnosed with cancer, the effects can be devastating both physically as well as financially. Recent studies have shown that many cancer patients are foregoing care because of the skyrocketing cost of cancer treatments.

22 Apr 2010

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs.

22 Apr 2010

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.

22 Apr 2010

Halo Benefits introduces new pharmacy prescription card that offers discounts to consumers

Halo Benefits, Inc., a subsidiary of Halo Companies, Inc., announced today that it now offers HaloRx, a pharmacy prescription card that offers discounts to consumers. The new discount card is offered now at a time when the cost of prescription drugs is at a record high. "We are excited about the opportunity to offer more affordable options to consumers with medication needs.

22 Apr 2010

Pharmaceutical News

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

pHase Pharmaceuticals launches new drug development company

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

CSL Biotherapies comments on influenza vaccine paediatric adverse events

FDA rejects experimental painkiller Acurox

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Colorcon acquires NP Pharm

IAVI, Lentigen to design preventive AIDS vaccine

FDA Advisory Committees vote against approval of Acurox NDA

Biostar Pharmaceuticals lists on NASDAQ Global Market

CRT teams up with The University of Auckland to discover novel treatments for cancer

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

FDA announces draft guidance expanding transparency, disclosure in conflict of interest waivers

CancerDrugsDirect.com provides customers access to affordable cancer medications

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

Halo Benefits introduces new pharmacy prescription card that offers discounts to consumers

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News